Dashboard
Manage Tickers

LSTA LISATA THERAPEUTICS, INC.

Nasdaq caladrius.com


$ 2.51 $ 0.09 (3.7 %)    

Thursday, 16-Oct-2025 16:39:30 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 593.20 $ 0.00 (0 %)
DIA $ 456.09 $ 0.00 (0 %)
SPY $ 654.51 $ 0.00 (0 %)
TLT $ 91.46 $ 0.00 (0 %)
GLD $ 399.41 $ 0.00 (0 %)
$ 2.52
$ 2.38
$ 2.36 x 1,200
$ 2.79 x 2,000
-- - --
$ 1.87 - $ 4.20
39,053
na
22.06M
$ -2.21
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 02-27-2025 01-01-1970 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-12-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 02-29-2024 12-31-2023 10-K
8 11-02-2023 09-30-2023 10-Q
9 08-14-2023 06-30-2023 10-Q
10 05-09-2023 03-31-2023 10-Q
11 03-30-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-04-2022 06-30-2022 10-Q
14 05-05-2022 03-31-2022 10-Q
15 03-22-2022 12-31-2021 10-K
16 11-04-2021 09-30-2021 10-Q
17 08-05-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 02-25-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
21 08-13-2020 06-30-2020 10-Q
22 05-07-2020 03-31-2020 10-Q
23 03-05-2020 12-31-2019 10-K
24 11-06-2019 09-30-2019 10-Q
25 08-08-2019 06-30-2019 10-Q
26 05-09-2019 03-31-2019 10-Q
27 03-14-2019 12-31-2018 10-K
28 11-08-2018 09-30-2018 10-Q
29 08-09-2018 06-30-2018 10-Q
30 05-10-2018 03-31-2018 10-Q
31 03-22-2018 12-31-2017 10-K
32 11-09-2017 09-30-2017 10-Q
33 08-10-2017 06-30-2017 10-Q
34 05-15-2017 03-31-2017 10-Q
35 03-17-2017 12-31-2016 10-K
36 11-07-2016 09-30-2016 10-Q
37 08-09-2016 06-30-2016 10-Q
38 05-05-2016 03-31-2016 10-Q
39 03-15-2016 12-31-2015 10-K
40 11-05-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

lisata-therapeutics-and-catalent-enters-global-antibody-drug-conjugate-license-agreement-lisata-therapeutics-to-receive-over-10m-in-milestone-payments
Lisata Therapeutics And Catalent Enters Gl...
10/08/2025 12:35:45

lisata-therapeutics-releseass-preliminary-results-from-pancreatic-ductal-adenocarcinoma-cohort-in-phase-12a-cendifox-trial-showing-certepetide-can-enhance-the-effectiveness-of-standard-of-care-chemotherapy-in-pancreatic-cancer
Lisata Therapeutics Releseass Preliminary ...
09/29/2025 12:06:00

Results to be presented at the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research—Emerging Scie...

hc-wainwright--co-reiterates-buy-on-lisata-therapeutics-maintains-15-price-target
HC Wainwright & Co. Reiterates Buy on Lisa...
08/21/2025 11:18:18

HC Wainwright & Co. analyst Joseph Pantginis reiterates Lisata Therapeutics (NASDAQ:LSTA) with a Buy and maintains $15 p...

lisata-therapeutics-q2-eps-054-beats-065-estimate-sales-7000k
Lisata Therapeutics Q2 EPS $(0.54) Beats $...
08/07/2025 20:36:05

Lisata Therapeutics (NASDAQ:LSTA) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $...

Core News & Articles
Earnings Scheduled For August 7, 2025
08/07/2025 08:33:15

Core News & Articles
12 Health Care Stocks Moving In Monday's P...
07/21/2025 12:08:15

lisata-therapeutics-and-warpnine-announce-completion-of-patient-enrollment-in-phase-1b2a-ilsta-trial-in-australia
Lisata Therapeutics And WARPNINE Announce ...
07/17/2025 12:04:57

brookline-capital-maintains-buy-on-lisata-therapeutics-raises-price-target-to-32
Brookline Capital Maintains Buy on Lisata ...
07/15/2025 15:21:58

Brookline Capital maintains Lisata Therapeutics (NASDAQ:LSTA) with a Buy and raises the price target from $20 to $32.

us-patent-and-trademark-office-issues-lisata-therapeutics-composition-of-matter-patent-for-certepetide-through-march-2040-with-opportunity-for-patent-term-extension
U.S. Patent And Trademark Office Issues Li...
07/15/2025 12:11:13

Newly issued U.S. patent extends certepetide IP protection to 2040, with subsequent opportunity for patent term extensionThis p...

agitg-nhmrc-clinical-trials-centre-at-university-of-sydney-and-lisata-therapeutics-announce-preliminary-cohort-b-data-from-ascend-phase-2b-trial-in-metastatic-pancreatic-cancer
AGITG, NHMRC Clinical Trials Centre At Uni...
06/26/2025 12:07:39

ASCEND comprises two dosing regimens of certepetide evaluated in two separate study arms enrolled sequentiallyPositive signal i...

lisata-therapeutics-and-gatc-health-announce-strategic-alliance-to-accelerate-and-improve-success-rate-of-traditional-drug-development-process
Lisata Therapeutics And GATC Health Announ...
06/17/2025 12:08:15

Expanded alliance combines Lisata's drug development expertise with GATC's AI-powered Multiomics Advanced Technology® p...

lisata-therapeutics-q1-eps-055-misses-053-estimate
Lisata Therapeutics Q1 EPS $(0.55) Misses ...
05/08/2025 20:09:52

Core News & Articles
Earnings Scheduled For May 8, 2025
05/08/2025 08:33:13

lisata-enters-into-research-license-with-catalent-to-evaluate-efficacy-of-lisatas-irgd-cyclic-peptide-product-candidate-certepetide-as-payload-used-in-smartag-adc-dual-payload-tech-platform
Lisata Enters Into Research License With C...
04/15/2025 12:04:59

BASKING RIDGE, N.J., April 15, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "C...

lisata-therapeutics-and-gatc-health-begin-strategic-collaboration-to-use-ai-to-derisk-and-accelerate-drug-development
Lisata Therapeutics And GATC Health Begin ...
03/05/2025 13:33:26

Strategic collaboration harnesses GATC's proprietary Artificial Intelligence-powered, validated Multiomics Advanced Technol...

lisata-therapeutics-q4-gaap-eps-055-beats-079-estimate
Lisata Therapeutics Q4 GAAP EPS $(0.55) Be...
02/27/2025 21:56:12

Lisata Therapeutics (NASDAQ:LSTA) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $...

earnings-scheduled-for-february-27-2025
Earnings Scheduled For February 27, 2025
02/27/2025 08:32:34

lisata-and-warpnine-announces-interim-phase-1b2a-results-for-certepetide-in-pancreatic-cancer-56-show-partial-response-after-4-cycles-with-up-to-90-reduction-in-ca19-9-levels-results-to-be-presented-at-2025-asco-gi-symposium
Lisata And WARPNINE Announces Interim Phas...
01/23/2025 13:12:38

Data corroborate previously reported preclinical data demonstrating certepetide's ability to enhance the effectiveness of i...

12-health-care-stocks-moving-in-wednesdays-pre-market-session
12 Health Care Stocks Moving In Wednesday'...
01/22/2025 21:05:44

crude-oil-edges-lower-abbott-laboratories-posts-weak-sales
Crude Oil Edges Lower; Abbott Laboratories...
01/22/2025 19:39:04

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION